Financings in Brief: Urohealth Systems
This article was originally published in The Gray Sheet
Executive Summary
Urohealth Systems: Firm's board approves the redemption of series A preferred stock issued by Davstar, Inc., Urohealth's wholly owned subsidiary, for a total consideration of $6.20 per share. The repurchase will eliminate dividend accumulation of the shares, which accrue at 7% per year, Urohealth says. The company's board also votes to approve a $20 mil. revolving line of credit proposal from Bankers Trust. Proceeds from the line of credit are tabbed for "working capital needs"...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.